MINNEAPOLIS--(BUSINESS WIRE)--Urologix®, Inc. (NASDAQ:ULGX) announced today presentation of long-term clinical results from a multi-center trial with the Urologix Cooled ThermoCath® (CTC) Microwave Catheter for treatment of benign prostatic hyperplasia (BPH), also known as enlarged prostate, at the 2008 American Urological Association meeting in Orlando, Florida. CTC is a Cooled Thermotherapy catheter that is used exclusively with the Urologix CoolWave® or Targis® control units. The therapy is delivered in the comfortable setting of a physician’s office with a treatment time of under 30 minutes. The results showed the efficacy of the CTC Microwave Catheter is durable for at least five years and the freedom from additional minimally invasive or surgical procedures is 90%. The data from the study showed clinically significant improvement from baseline of the three major BPH evaluation criteria: urinary flow rate, symptom improvement, and quality of life at the 5-year follow-up.
